SVP Academic Partnerships
Evotec (UK) Ltd, England, United Kingdom
Adam Stoten PHD, RTTP
Dr Adam Stoten is SVP Academic Partnerships at Evotec SE, a global multi-modality drug discovery and development company, where he is responsible for creating new international BRIDGE partnerships to accelerate the translation of academic science into new therapeutics. Prior to Evotec, Dr Stoten was Chief Operating Officer and board director at Oxford University Innovation Ltd (OUI). While at OUI he was a member of the team that negotiated the Oxford COVID vaccine partnership with AstraZeneca, was a founding director of Vaccitech Ltd and EvOx Therapeutics Ltd and was a co-architect of Evotec's first BRIDGE; LAB282. Between 2010 and 2013 Dr Stoten worked as Deputy General Manager for a joint venture between the University of Oxford and Emergent BioSolutions Inc, developing a next generation TB vaccine. Prior to this Dr Stoten worked in healthcare consulting and then in increasingly senior commercialisation roles at Isis Innovation. Dr Stoten also serves as a board member of both PraxisAuril, the UK professional association for knowledge exchange practitioners, and of ATTP, the body that maintains internationally recognised standards for the knowledge and technology transfer profession.
Disclosure information not submitted.
Tuesday, February 8, 2022
2:30 PM – 3:10 PM